- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01885065
Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients
June 19, 2013 updated by: Dental Innovation Foundation Under Royal Patronage
Efficacy Study of Novel Edible Gel-based Artificial Saliva in Xerostomic Cancer Patients
The purpose of this study is to determine whether continuous use of edible, gel-based artificial saliva in cancer patients with dry mouth problems will reduce signs and symptoms of dry mouth and improve quality of patients' saliva.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Pathumthani, Thailand, 12110
- Mahavachiralongkorn cancer hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- cancer patients who receive/ had received radiotherapy and/or chemotherapy and have dry mouth problems
Exclusion Criteria:
- mucositis more than grade 1
- cannot perform oral intake of gel-based artificial saliva eg. aspirate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Gel-based artificial saliva
Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
|
Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth. Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in subjective dry mouth score
Time Frame: baseline, 2 weeks and 4 weeks after intervention
|
The outcome measure (subjective dry mouth score) will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week)
|
baseline, 2 weeks and 4 weeks after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in objective dry mouth score
Time Frame: Baseline, 2 week and 4 weeks after the start date
|
The outcome measure will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week)
|
Baseline, 2 week and 4 weeks after the start date
|
Changes in salivary pH
Time Frame: Baseline, 2 weeks and 4 weeks after the start date
|
The outcome measure will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week)
|
Baseline, 2 weeks and 4 weeks after the start date
|
Changes in salivary buffering capacity
Time Frame: Baseline, 2 weeks and 4 weeks after the start date
|
The outcome measure will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week)
|
Baseline, 2 weeks and 4 weeks after the start date
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Aroonwan Lam-ubol, DDS, PhD, Faculty of Dentistry, Srinakharinwirot University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (ACTUAL)
September 1, 2012
Study Completion (ACTUAL)
December 1, 2012
Study Registration Dates
First Submitted
June 16, 2013
First Submitted That Met QC Criteria
June 19, 2013
First Posted (ESTIMATE)
June 24, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
June 24, 2013
Last Update Submitted That Met QC Criteria
June 19, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIF-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Gel-based artificial saliva
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Thammasat University; Srinakharinwirot...CompletedHypertension | Diabetes Mellitus | XerostomiaThailand
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Srinakharinwirot UniversityCompletedDry Mouth | Radiation-Induced Xerostomia | Cancer of Head NeckThailand
-
Laboratoires CARILENEDERMSCAN-PHARMASCAN GROUP in charge of data analysisCompleted
-
University of PennsylvaniaCompleted
-
Certmedica International GmbHCompletedDiabetes Mellitus, Type 2 | Xerostomia Due to Hyposecretion of Salivary GlandItaly
-
Xiao-dong ZhuangRecruitingValvular Heart DiseaseChina
-
Cairo UniversityNot yet recruitingOral Cancer | Leukoplakia | Oral Lichen Planus | Erythroplakia | Fordyce Granule | Leukoedemas, Oral | Lichenoid Reaction
-
University of PennsylvaniaCompleted
-
Technische Universität DresdenRecruitingInvasive Mechanical VentilationSwitzerland, Germany, Spain, United States, Serbia
-
Izmir Tinaztepe UniversityCompleted